GlassScriptPhysician profile
Yitzhak Daniel Haim
NPI 1831178698
$16,100.13
in general payments reported to CMS, 2019-2025
52 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,162 · 2020: $589 · 2021: $1,061 · 2022: $1,084 · 2023: $384 · 2024: $2,672 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,402 · Travel and Lodging: $1,717 · Education: $84.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.49 |
| Travel and Lodging | $1,716.67 |
| Education | $84.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,765.52 | 2019-2025 | Ofev, Jascayd |
| Pulmonx Corporation | $1,192.06 | 2021-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $939.36 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $882.00 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Ethicon INC. | $847.97 | 2019-2025 | Monarch Platform |
| Olympus Corporation of The Americas | $842.65 | 2019 | |
| Glaxosmithkline, LLC. | $715.59 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $363.68 | 2019-2025 | |
| Insmed, INC. | $280.20 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $240.73 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $212.13 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $192.31 | 2019-2022 | |
| Grifols USA, LLC | $160.66 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $106.67 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.37 | 2019-2025 |
Show all 48 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yitzhak Daniel Haim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.